SCHEMBL13680204

SCHEMBL13680204

COc1cc2ncnc(Oc3ccccc3)c2cc1OC

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.73
EGFR P00533 4/20 0.73
LCK P06239 2/20 0.73
RET P07949 1/20 0.73
KIF5B P33176 1/20 0.73
CSF1R P07333 2/20 0.70
PDGFRB P09619 1/20 0.67
FLT4 P35916 1/20 0.67
FLT3 P36888 1/20 0.67
BRAF P15056 2/20 0.67
RIPK2 O43353 1/20 0.62
EPHB2 P29323 1/20 0.62
PDGFRA P16234 2/20 0.62
RAF1 P04049 1/20 0.61
TRPA1 O75762 1/20 0.60
KIT P10721 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18158553 0.97 KDR (0.70) KDREGFRLCKRETKIF5B
SCHEMBL4023315 0.91 PDGFRB (0.75) KDREGFRLCKRETKIF5B
SCHEMBL17278108 0.90 KDM1A (0.73) KDREGFRLCKRETKIF5B
SCHEMBL4025375 0.89 KDR (0.67) KDREGFRLCKRETKIF5B
SCHEMBL7214444 0.89 KDR (0.63) KDREGFRLCKRETKIF5B
SCHEMBL4359665 0.87 CSF1R (0.81) KDREGFRLCKRETKIF5B
SCHEMBL7209956 0.87 KDR (0.58) KDREGFRLCKRETKIF5B
SCHEMBL7452950 0.87 PDGFRB (0.66) KDREGFRLCKRETKIF5B
SCHEMBL4373197 0.86 KDM1A (0.76) KDREGFRLCKRETKIF5B
SCHEMBL20229657 0.86 KDR (0.74) KDREGFRLCKRETKIF5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3147281-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2017-03-29 EP disclosed
EP-2947072-A1 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES Ambit Biosciences Corporation (US) 2015-11-25 EP disclosed
EP-2268623-B1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2015-05-06 EP disclosed
WO-2009117080-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATON (US) 2009-09-24 WO disclosed